Research programme: haemophilia therapeutics - Ipsen/Inspiration Biopharmaceuticals

Drug Profile

Research programme: haemophilia therapeutics - Ipsen/Inspiration Biopharmaceuticals

Alternative Names: IB 1007; IB 1008

Latest Information Update: 27 Feb 2014

Price : $50

At a glance

  • Originator Inspiration Biopharmaceuticals; Ipsen
  • Developer Emergent BioSolutions
  • Class Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 10 Jun 2013 Cangene Corporation completes acquisition of IB 1007 and IB 1008 from Ipsen and Inspiration Biopharmaceuticals
  • 06 Feb 2013 Inspiration and Ipsen agree to sell all rights and related assets to a preclinical haemophilia programme to Cangene Corporation subject to closing conditions
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top